Phibro Animal Health (NASDAQ:PAHC) had its price objective boosted by Morgan Stanley from $30.00 to $36.00 in a research note released on Wednesday morning. The brokerage currently has an underweight rating on the stock.
Other equities research analysts have also issued reports about the company. Piper Jaffray Companies reissued a buy rating and set a $42.00 price target on shares of Phibro Animal Health in a research report on Friday, November 10th. Zacks Investment Research raised Phibro Animal Health from a hold rating to a buy rating and set a $41.00 price target on the stock in a research report on Tuesday, October 31st. ValuEngine lowered Phibro Animal Health from a buy rating to a hold rating in a research report on Thursday, November 9th. Credit Suisse Group upped their price target on Phibro Animal Health from $37.00 to $39.00 and gave the company a neutral rating in a research report on Tuesday. Finally, BidaskClub raised Phibro Animal Health from a strong sell rating to a sell rating in a research report on Thursday, December 21st. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. The stock has an average rating of Hold and a consensus price target of $38.20.
Shares of Phibro Animal Health (PAHC) opened at $36.60 on Wednesday. The company has a debt-to-equity ratio of 1.82, a quick ratio of 1.85 and a current ratio of 3.12. The stock has a market capitalization of $1,460.65, a P/E ratio of 23.01, a P/E/G ratio of 3.97 and a beta of 1.18. Phibro Animal Health has a 52-week low of $26.70 and a 52-week high of $40.25.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 28th. Shareholders of record on Wednesday, March 7th will be given a $0.10 dividend. This represents a $0.40 annualized dividend and a yield of 1.09%. The ex-dividend date of this dividend is Tuesday, March 6th. Phibro Animal Health’s dividend payout ratio is presently 26.14%.
Hedge funds and other institutional investors have recently modified their holdings of the business. First Manhattan Co. acquired a new stake in Phibro Animal Health in the fourth quarter worth $100,000. Dean Capital Investments Management LLC acquired a new stake in Phibro Animal Health in the fourth quarter worth $200,000. Susquehanna International Group LLP acquired a new stake in Phibro Animal Health in the second quarter worth $219,000. Teacher Retirement System of Texas acquired a new stake in Phibro Animal Health in the fourth quarter worth $224,000. Finally, Crossmark Global Holdings Inc. acquired a new stake in Phibro Animal Health in the fourth quarter worth $253,000. 48.31% of the stock is currently owned by hedge funds and other institutional investors.
Phibro Animal Health Company Profile
Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.